EPx4 Raises Odds of Renal, Nerve, Hearing Harms - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

  • By

  • Kerri Miller

  • February 25, 2026

  • 5 min

Share

Original Source(s)

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

  • by Kerri Miller

  • February 25, 2026

Related Content

FDA approves first therapy for warm autoimmune hemolytic anemia

The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.

10 Growing US Metro Areas to Consider for Private Practice

These 10 metropolitan areas recorded population growth and had recently completed, ongoing, or announced health care infrastructure projects.